home All News open_in_new Full Article

Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid

Safety Review Committee Found No Safety Concerns Following Milestone Trial TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced that it has completed its trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and […]


today 5 h. ago attach_file Other

attach_file Culture
attach_file Other
attach_file Culture
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Sport
attach_file Other
attach_file Politics
attach_file Events
attach_file Economics
attach_file Other


ID: 4178710500
Add Watch Country

arrow_drop_down